Mean reductions in CRT at 6months were 177.1122.3 m in the ranibizumab group ( p < 0.0001 ) and 201.7166.2 m in the bevacizumab group ( p < 0.0001 ) , with no significant difference between the two groups ( p = 0.48 ) .